3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorShengjing Hospital

About this trial

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.

Eligibility criteria

Qualifiers

age > 18 years old

confirmed cirrhosis (laboratory, imaging and clinical symptoms)

with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement

written informed consent

Disqualifiers

any previous liver or spleen surgery

liver cancer; chronic acute liver failure

acute portal hypertension

unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons

Trial design

Treatments tested in this trial

  • 3D-MRE
  • HVPG
  • 2D-MRE
  • HVPG

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators